Report Overview

Indian Hereditary Angioedema (HAE) Therapeutics market size stood at around USD XX Billion in 2019 and is projected to reach USD XX million by 2028, exhibiting a CAGR of XX% during the forecast period.

Hereditary angioedema (HAE) is a rare disorder related with the immune system. The life-threatening condition is caused due to the lack of C1-esterase inhibitor (C1-INH) causing the blood vessels to dilate. The symptoms of the disease include recurrent episodes of edema in various body parts such as hands, feet, face and airways. HAE is classified into 3 types: Type I HAE, Type II HAE and Type III HAE based on the reduction in its synthesis of inhibitor or the formation of a dysfunctional protein. Although, the condition is hereditary, the absence of a family history does not rule out the diagnosis of HAE, indicating that as many as 25% of HAE cases result from a spontaneous mutation of the C1-inhibitor gene at conception.



Market Drivers

The major factor driving growth of the hereditary angioedema market include intense R&D initiatives by the manufacturers to treat the condition, increasing prevalence of hereditary angioedema and the presence of promising drug pipeline. Increasing awareness about the disorder and rising prevalence of the hereditary angioedema are some factors expected to drive the global Hereditary Angioedema Treatment Market during the forecast period. Additionally, technological developments in the hereditary angioedema treatment devices and equipment is expected to boost the Indian market.